ÂÜÀòÂÒÂ×

Dr. Charles Schweizer is responsible for clinical development strategy and operational execution at ImmunoGenesis. He has 25 years of clinical product development, regulatory, and operations experience across pharmaceutical companies, biotechs, and Contract Research Organizations (CROs) focused in oncology. Before joining ImmunoGenesis, Dr. Schweizer was Therapeutic Area Head, Oncology, at GlaxoSmithKline (GSK), where he oversaw a global oncology portfolio of early and commercial-stage assets. Prior to GSK, he was Vice President, Clinical Operations, at Galera Therapeutics, a biotech developing oncology radiotherapeutics.

Dr. Schweizer’s earlier senior management positions include Vice President, Pharmaceutical Product Development, for over 12 years at Morphotek, a biologics subsidiary of Eisai developing novel oncology monoclonal antibodies and antibody-drug conjugates. As the head of clinical product development, he was responsible for clinical and regulatory strategy, operational execution, and cross-functional alignment of the clinical pipeline at all development stages. He joined Morphotek following operational and program management roles at PRA International, a large global CRO.

He holds a PhD in Health Policy and Epidemiology from the University of the Sciences in Philadelphia (formerly Philadelphia College of Pharmacy and Science) and the University of Pennsylvania. He has presented and published numerous manuscripts and research abstracts on topics across cancer research.